SCH 57790
Latest Information Update: 25 Jun 2001
At a glance
- Originator Schering-Plough
- Class Neuroprotectants; Nootropics; Piperazines
- Mechanism of Action Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 25 Jun 2001 No-Development-Reported for Cognition disorders in USA (Unknown route)
- 14 Dec 1998 New profile
- 14 Dec 1998 Preclinical development for Cognition disorders in USA (Unknown route)